John Hussman's UTHR Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 14.7K shares of United Therapeutics Corporation (UTHR) worth $0, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, John Hussman has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2020, adding 15.5K shares. Largest reduction occurred in Q4 2013, reducing 224.0K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +468,001 | Add 0.00% | 468,000 | $65.82 |
| Q3 2013 | -110,000 | Reduce 23.50% | 358,000 | $78.85 |
| Q4 2013 | -224,000 | Reduce 62.57% | 134,000 | $113.08 |
| Q3 2014 | -84,000 | Reduce 62.69% | 50,000 | $128.64 |
| Q1 2015 | -25,000 | Reduce 50.00% | 25,000 | $172.44 |
| Q4 2015 | -25,000 | Sold Out | 25,000 | $0.00 |
| Q1 2017 | +25,500 | New Buy | 25,500 | $135.37 |
| Q2 2017 | -250 | Reduce 0.98% | 25,250 | $129.74 |
| Q3 2017 | -250 | Reduce 0.99% | 25,000 | $117.20 |
| Q4 2017 | -15,000 | Reduce 60.00% | 10,000 | $147.90 |
| Q1 2018 | -10,000 | Sold Out | 10,000 | $0.00 |
| Q1 2019 | +25,000 | New Buy | 25,000 | $117.36 |
| Q3 2019 | -15,000 | Reduce 60.00% | 10,000 | $79.80 |
| Q4 2019 | -10,000 | Sold Out | 10,000 | $0.00 |
| Q3 2020 | +25,500 | New Buy | 25,500 | $101.02 |
| Q4 2020 | -15,300 | Reduce 60.00% | 10,200 | $151.76 |
| Q1 2021 | +600 | Add 5.88% | 10,800 | $167.22 |
| Q2 2021 | -3,600 | Reduce 33.33% | 7,200 | $179.44 |
| Q3 2021 | -4,100 | Reduce 56.94% | 3,100 | $184.52 |
| Q4 2021 | -500 | Reduce 16.13% | 2,600 | $216.15 |
| Q1 2022 | -2,600 | Sold Out | 2,600 | $0.00 |
| Q2 2023 | +9,300 | New Buy | 9,300 | $220.75 |
| Q3 2023 | -9,300 | Sold Out | 9,300 | $0.00 |
| Q3 2024 | +6,300 | New Buy | 6,300 | $358.35 |
| Q4 2024 | +2,100 | Add 33.33% | 8,400 | $352.84 |
| Q1 2025 | +4,200 | Add 50.00% | 12,600 | $308.27 |
| Q2 2025 | +2,100 | Add 16.67% | 14,700 | $287.35 |
| Q3 2025 | -14,700 | Sold Out | 14,700 | $0.00 |
John Hussman's United Therapeutics Corporation Investment FAQs
John Hussman first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 468,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held United Therapeutics Corporation (UTHR) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2013, adding 468,000 shares worth $30.8 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 14,700 shares of United Therapeutics Corporation (UTHR), valued at approximately $0. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.00% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in United Therapeutics Corporation (UTHR) was 468,000 shares, as reported at the end of Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.